Aim 1: To co-develop the "Patient-Centered Pharmacy Pathway for Oral Chemotherapy" (P3OC) components through stakeholder engagement by conducting a modified Delphi panel with pharmacists, physicians, and other oncology healthcare providers (36,37) to determine key symptoms to assess during oral chemotherapy. Aim 2: To conduct usability testing(38,39) of the P3OC EHR Smart Form, verbal PROM, and report/dashboard with pharmacists.

This study will evaluate the safety and tolerability of EG 70, a gene therapy, which is given inside the bladder, and its effectiveness on eliminating bladder tumors in patients with NMIBC who have failed BCG therapy and have been recommended to have their bladder removed. Giving the study drug inside the bladder is to expose cells in the lining of the bladder, including your cancerous cells, to genes that may cause an immune response inside the bladder and kill the tumor cells.

Purpose: to establish a Registry of pediatric patients treated with proton radiation therapy. Participants: Patients who are less than or equal to 21 years old at time of treatment start and treated with radiation therapy at one of the participating centers. Procedures (methods): This Proton and Photon Consortium Registry (PPCR) enrolls children treated with radiation therapy to form an expansive description of the pediatric population that receives protons and to better catalogue the benefits of protons, in this cohort. The data will also be used to evaluate practice differences and help facilitate collaborative research across the various radiation centers. The PPCR collects an expanded set of demographic and clinical data that will enhance the practice data that many participating radiation centers already collect in their routine operations. The PPCR has been expanded to include a photon-treated control group, helping to facilitate comparative effectiveness analysis.

To create digital tools to support young adult cancer survivors completing active treatment and transitioning into survivorship care.

This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients with relapsed B-ALL are included in this study. Blinatumomab is an antibody, which is a protein that identifies and targets specific molecules in the body. Blinatumomab searches for and attaches itself to the cancer cell. Once attached, an immune response occurs which may kill the cancer cell. Nivolumab is a medicine that may boost a patient's immune system. Giving nivolumab in combination with blinatumomab may cause the cancer to stop growing for a period of time, and for some patients, it may lessen the symptoms, such as pain, that are caused by the cancer.

We are determining whether upper extremity function improves after surgery for patients presenting with upper extremity lymphedema.

This study seeks to understand how best to increase knowledge about clinical trials, best way of communicating information about clinical trials, and suggestions for improving clinical trial participation particularly among African Americans (AA).

The purpose of this research study is to create a Lymphoma Registry of patients who are willing to complete the study's comprehensive assessment. The assessment is designed to gather information on memory, nutritional status, mental health, and level social support. It is also designed to understand how well you carry out your day to day activities and to briefly describe what other medical conditions you may have. This assessment will help your health care team determine your "functional age" (the age you function at) as compared to how many years old you are. We will also ask you to complete questionnaires that ask questions about your personal health history, such as exercise and smoking,

The goal of the study is to determine why some men and women get certain types of head and neck (mouth or throat) cancer, and others do not. If we can identify underlying causes of head and neck cancer, we can determine ways to prevent it from occurring. Collection and analysis of medical records and tumor biology may also lead to more effective treatments and lower the death rate from this disease.

To find out if the addition of 2 blocks of inotuzumab ozogamicin to the standard chemotherapy regimen will improve outcomes in children and young adults with High-Risk (HR) B-cell acute lymphoblastic leukemia (B-ALL).